AbCellera Biologics vs Recursion Pharmaceuticals
ABCL and RXRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABCL and RXRX compare
AbCellera Biologics is the larger company, worth 2.1 times as much as Recursion Pharmaceuticals ($3.5B against $1.7B).
AbCellera Biologics grew revenue faster over the last twelve months (92.1% versus 56.2% for Recursion Pharmaceuticals).
AbCellera Biologics keeps more of each dollar of sales as profit, with a net margin of −219% compared with −697% at Recursion Pharmaceuticals.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABCL | RXRX |
|---|---|---|
| Size and price | ||
| Market cap | $3.5B | $1.7B |
| Share price | $11.49 | $3.19 |
| Change, 1 year | 189% | −31.5% |
| Change, 5 years | −27.3% | −83.9% |
| Beta (5Y) | 1.46 | 2.65 |
| Employees | 562 | 50 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 0 | 1 (better) |
| Growth score | 1 | 3 (better) |
| Performance score | 1 | 2 (better) |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 51.9× | 25.0× (better) |
| P/B | 3.3× | 1.9× (better) |
| FCF yield | −0.93% (better) | −18.3% |
| Fair value | $4.50 | $3.14 |
| Margin of safety | −155% | −1.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 92.1% (better) | 56.2% |
| Revenue growth, 5Y average | −20.3% | 79.9% (better) |
| Profitability | ||
| Gross margin | – | 29.2% |
| Operating margin | −298% (better) | −725% |
| Net margin | −219% (better) | −697% |
| FCF margin | −48.4% (better) | −458% |
| Return on equity | −14.6% (better) | −48.7% |
| Return on invested capital | −41.7% (better) | −102% |
| Financial health | ||
| Debt / equity | 0.00 | 0.01 (better) |
| Interest coverage | – | −541.6× |
| Current ratio | 12.43 (better) | 5.01 |
| Altman Z-score | 4.92 (better) | −0.36 |
| Piotroski F-score | 5 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | −12.8% |
| Shareholder yield | 0.00% (better) | −12.8% |
| Ownership | ||
| Held by institutions | 37.9% | 67.6% |
| Held by insiders | 22.8% | 5.6% |
| Insider net buying, 12 months | $3.2M (better) | −$7.4M |
| Short interest, % of float | 12.3% | 28.2% |
Go deeper
- ABCL stock overview
- ABCL income statement
- ABCL valuation and score
- RXRX stock overview
- RXRX income statement
- RXRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.